CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)	3 Months Ended
	Mar. 31, 2022 EUR (€) shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 EUR (€) shares	Mar. 31, 2021 USD ($) $ / shares shares
Revenues
Research and development services | $		$ 0		$ 3
Advisory services	€ 3,000		€ 0
Grants	482,000		131,000
Total revenues	485,000		134,000
Expenses
Research and development	582,000		254,000
General and administrative	332,000		291,000
Total expenses	914,000		545,000
Operating loss	(429,000)		(411,000)
Interest expense	694,000		685,000
Other (income) expense	88,000		122,000
Loss before income tax provision	(1,211,000)		(1,218,000)
Income tax provision	0		(28,000)
Net loss	(1,211)	(1,211)	(1,246)	$ (1,246)
Other Comprehensive Loss
Foreign currency translation adjustment	7	$ 7	(8)
Comprehensive loss	€ (1,204,000)		€ (1,254,000)
Basic and diluted loss per share | $ / shares		$ (0.00)		$ (0.00)
Weighted average number of shares used in per share calculations | shares	303,757,622	303,757,622	303,757,622	303,757,622